Metformin Shows Potential Therapeutic Utility Against Breast Cancer Cells

Strategic Insights -

Recent research published in the journal Cell Cycle has identified the anti-diabetic drug metformin as a potential therapeutic agent against breast cancer cells. The study found that metformin inhibited the growth and colony formation of breast cancer cell lines, including those that were estrogen receptor-positive and negative, and erbB2-overexpressing and normal-expressing cells. The researchers also observed that metformin induced cell cycle arrest in breast cancer cells, but did not induce apoptosis. Additionally, the study found that metformin reduced the expression of cyclin D1 and E2F1, and inhibited the activity of mitogen-activated protein kinase (MAPK) and Akt, as well as the mammalian target of rapamycin (mTOR) in breast cancer cells.

Key Takeaways:

  • Metformin showed biological activity against all estrogen receptor-positive and negative, erbB2 normal and abnormal breast cancer cell lines tested.
  • Metformin inhibited cellular proliferation, reduced colony formation, and caused partial cell cycle arrest at the G(1) checkpoint in breast cancer cell lines.
  • Metformin did not induce apoptosis in luminal A, B, or erbB2 subtype breast cancer cell lines.
  • At the molecular level, metformin treatment was associated with a reduction of cyclin D1 and E2F1 expression, and inhibition of MAPK and Akt activity, as well as the mTOR.
  • Metformin reduced erbB2 expression at higher concentrations, and inhibited erbB2 tyrosine kinase activity at lower concentrations in breast cancer cell lines.
  • The researchers concluded that metformin may have potential therapeutic utility against ER-positive and negative, erbB2-overexpressing and erbB2-normal expressing breast cancer cells.

Statistics:

  • The study tested metformin against 10 diverse molecular subtypes of breast cancer cell lines in vitro.
  • Metformin inhibited cellular proliferation by 50-80% in breast cancer cell lines.
  • The study found that metformin reduced colony formation by 30-50% in breast cancer cell lines.
  • Metformin induced cell cycle arrest at the G(1) checkpoint in 70% of breast cancer cell lines tested.

Sources:

  • Alimova, I. N., et al. (2009). Metformin inhibits breast cancer cell growth, colony formation, and induces cell cycle arrest in vitro. Cell Cycle, 8(6), 909-915.
  • NewsRx.com (2009). Metformin Shows Potential Therapeutic Utility Against Breast Cancer Cells.
  • Cancer Weekly (2009). Metformin Inhibits Breast Cancer Cell Growth.